Daxor continues development of BVA-100:
This article was originally published in Clinica
Executive Summary
Daxor (US) is to continue development of its BVA-100 blood volume analyser now that production of its albumin I-131 isotope has been approved by the US FDA. A suspended 510(k) application for the BVA-100 will now continue after eight years waiting for approval of the isotope. Iodine-131 is essential for measuring blood volume and will be part of the test kit for the New York-based company's analyser used during surgery. The albumin I-131 will be manufactured by Texas-based Iso-Tex Diagnostics.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.